Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Key Takeaways

• Zoci achieved 53.7% intracranial ORR in SCLC brain metastases
• 62.5% iORR observed at 1.6 mg/kg dose
• NEC cohort showed 38.2% overall response rate
• Grade ≥3 treatment‑related adverse events occurred in 19.9% of patients
• Global Phase 3 trial underway; registrational studies slated for 2026

Pulse Analysis

The emergence of DLL3 as a therapeutic target has reshaped the landscape for small‑cell lung cancer, a disease historically limited to chemotherapy and radiation. Zai Lab’s Zoci, a first‑in‑class antibody‑drug conjugate, leverages a potent cytotoxic payload to bind DLL3‑expressing tumor cells, delivering drug directly to the malignant site. By focusing on intracranial disease—a frequent cause of rapid decline—Zoci addresses a critical gap where conventional systemic agents struggle to cross the blood‑brain barrier, positioning the ADC as a potential new standard for brain‑metastatic SCLC.

Clinical readouts from the ongoing Phase 1 study reveal striking intracranial activity: more than half of evaluable patients experienced tumor shrinkage, with complete responses observed at the 1.6 mg/kg dose level. Importantly, these responses occurred regardless of prior radiotherapy, suggesting Zoci’s mechanism may complement existing local treatments rather than replace them. Safety signals remain manageable; Grade ≥3 adverse events affected roughly one‑fifth of participants, dominated by hematologic toxicities that are typical of ADC platforms. Compared with historical outcomes—where intracranial response rates rarely exceed 20%—Zoci’s efficacy represents a substantial leap forward.

Strategically, the data accelerate Zai Lab’s ambition to launch its first global oncology product. The ongoing Phase 3 trial in second‑line‑plus SCLC, coupled with planned first‑line and neuroendocrine carcinoma registrational studies for 2026, creates a clear regulatory pathway. Success would not only diversify Zai Lab’s revenue beyond its China‑centric portfolio but also reinforce the value of its U.S.–China R&D model. Moreover, the concurrent development of LRRC15‑targeting ADC ZL‑6201 and bispecific immunocytokine ZL‑1222 underscores a broader pipeline aimed at capturing multiple tumor‑type markets, amplifying investor interest and potential partnership opportunities.